GS
AXSM icon

GTS Securities’s Axsome Therapeutics AXSM Stock Holding History

GTS Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,400
Closed -$2.46M – 1488
2024
Q3 		$2.46M Buy
27,400
+4,200
+18% +$367K 0.01% 1421
2024
Q2 		$1.87M Sell
23,200
-13,100
-36% -$970K ﹤0.01% 1552
2024
Q1 		$2.9M Sell
36,300
-39,700
-52% -$3.33M 0.01% 1229
2023
Q4 		$6.05M Buy
76,000
+24,100
+46% +$1.61M 0.01% 879
2023
Q3 		$3.63M Buy
+51,900
New +$3.88M 0.01% 1115

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GTS Securities's AXSM Position: Q4 2024 in Review

GTS Securities sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 7,888 shares — an estimated $709K sold.

GTS Securities first reported a position in AXSM in Q2 2023 and held it in 6 quarters. The position peaked at $1.48M in Q1 2024. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • GTS Securities reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 7,888 Axsome Therapeutics shares in Q4 2024, an estimated $709K.
  • GTS Securities first reported a position in Axsome Therapeutics in Q2 2023 and held it in 6 quarters.
  • GTS Securities's Axsome Therapeutics position peaked at $1.48M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.